Kunwei Shen

List of Publications by Year
in descending order

103 papers	2,489 citations	430874 18 h-index	223800 46 g-index
113 all docs	113 docs citations	113 times ranked	3921 citing authors

#	Article	IF	Citations
1	Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer. Clinical Breast Cancer, 2022, 22, e147-e156.	2.4	1
2	Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy. Scientific Reports, 2022, 12, 2169.	3.3	2
3	Association of machine learning ultrasound radiomics and disease outcome in triple negative breast cancer.. American Journal of Cancer Research, 2022, 12, 152-164.	1.4	0
4	Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients. Frontiers in Oncology, 2022, 12, .	2.8	4
5	Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component. British Journal of Cancer, 2021, 124, 975-981.	6.4	2
6	Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199667.	3.2	8
7	Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment. Frontiers in Oncology, 2021, 11, 636266.	2.8	4
8	A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50Âyears of age. Journal of Translational Medicine, 2021, 19, 75.	4.4	3
9	Abstract PS17-38: Comprehensive association analysis of 21-gene recurrence score and overweight in breast cancer patients. , 2021, , .		0
10	Abstract PS4-28: Efficacy of adjuvant chemotherapy stratified by age and the 21 gene recurrence score in estrogen receptor positive breast cancer. , 2021, , .		0
11	CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 646774.	3.7	6
12	Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 619840.	2.8	5
13	A novel metabolic gene signature-based nomogram to predict overall survival in breast cancer. Annals of Translational Medicine, 2021, 9, 367-367.	1.7	7
14	Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis. Frontiers in Oncology, 2021, 11, 629666.	2.8	43
15	Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study. Breast Cancer Research and Treatment, 2021, 187, 759-768.	2.5	4
16	Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothened Antagonists. Cancer Research, 2021, 81, 3105-3120.	0.9	9
17	BFAR coordinates TGFÎ² signaling to modulate Th9-mediated cancer immunotherapy. Journal of Experimental Medicine, 2021, 218, .	8.5	14
18	Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer. OncoTargets and Therapy, 2021, Volume 14, 3611-3624.	2.0	1

#	Article	IF	Citations
19	Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer. Breast, 2021, 57, 71-79.	2.2	8
20	Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer. BMC Cancer, 2021, 21, 707.	2.6	1
21	Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients. BMC Cancer, 2021, 21, 807.	2.6	1
22	Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 638619.	2.8	9
23	Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis. Cancer Management and Research, 2021, Volume 13, 6279-6289.	1.9	3
24	21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients. Frontiers in Endocrinology, 2021, 12, 725161.	3.5	2
25	A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study. Journal of Medical Internet Research, 2021, 23, e27576.	4.3	13
26	Association of tumor‑infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. Cancer Medicine, 2021, 10, 7921-7933.	2.8	12
27	Identification of a novel immune-related prognostic signature associated with tumor microenvironment for breast cancer. International Immunopharmacology, 2021, 100, 108122.	3.8	11
28	Predictors of Nodal Pathological Complete Response in Asian Women with Stage II‑III Node-Positive Breast Cancer. Oncology, 2021, 99, 359-364.	1.9	2
29	Prognostic Factors and Surgery for Breast Cancer Patients With Locoregional Recurrence: An Analysis of 5,202 Consecutive Patients. Frontiers in Oncology, 2021, 11, 763119.	2.8	3
30	Impact of Different Modules of 21-Gene Assay in Early Breast Cancer Patients. Frontiers in Endocrinology, 2021, 12, 759338.	3.5	2
31	Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.. American Journal of Cancer Research, 2021, 11, 6188-6199.	1.4	0
32	Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia. JAMA Oncology, 2020, 6, e193692.	7.1	94
33	Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer. Journal of Geriatric Oncology, 2020, 11, 843-849.	1.0	5
34	ASO Author Reflections: Core Needle Biopsy and Hormonal Receptor Retesting in Breast Cancer: Controversy and Management. Annals of Surgical Oncology, 2020, 27, 731-732.	1.5	0
35	A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. BMC Cancer, 2020, 20, 663.	2.6	13
36	Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes. Cancer Medicine, 2020, 9, 6173-6185.	2.8	6

#	Article	IF	Citations
37	HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab. Breast, 2020, 54, 235-241.	2.2	10
38	Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells. Frontiers in Oncology, 2020, 10, 600487.	2.8	10
39	Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients. Frontiers in Oncology, 2020, 10, 1315.	2.8	3
40	Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis. Breast Cancer Research and Treatment, 2020, 184, 193-202.	2.5	11
41	Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast Cancer Risk in Chinese Women . OncoTargets and Therapy, 2020, Volume 13, 8027-8036.	2.0	5
42	A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 1335.	2.8	2
43	Validation of the Prognostic Stage of American Joint Committee on Cancer Eighth Edition Staging Manual in Invasive Lobular Carcinoma Compared to Invasive Ductal Carcinoma and Proposal of a Novel Score System. Frontiers in Oncology, 2020, 10, 1471.	2.8	6
44	Associations Between Circulating Insulin-Like Growth Factor 1 and Mortality in Women With Invasive Breast Cancer. Frontiers in Oncology, 2020, 10, 1384.	2.8	7
45	Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study. Frontiers in Oncology, 2020, 10, 580112.	2.8	37
46	Adipocytes promote breast tumorigenesis through TAZ-dependent secretion of Resistin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 33295-33304.	7.1	37
47	Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis. Journal of Cancer, 2020, 11, 6916-6924.	2.5	8
48	Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?. Frontiers in Oncology, 2020, 10, 708.	2.8	2
49	A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093267.	3.2	18
50	Compliance with multidisciplinary team recommendations and disease outcomes in early breast cancer patients: An analysis of 4501 consecutive patients. Breast, 2020, 52, 135-145.	2.2	11
51	Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients. Journal of Cancer, 2020, 11, 2602-2609.	2.5	0
52	Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score. Journal of Cancer, 2020, 11, 2509-2517.	2.5	1
53	Single‐cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Communications, 2020, 40, 329-344.	9.2	110
54	Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients. Scientific Reports, 2020, 10, 7029.	3.3	14

#	Article	IF	Citations
55	IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients. Frontiers in Oncology, 2020, 10, 550.	2.8	11
56	A Decision Support System with Intelligent Recommendation for Multi-disciplinary Medical Treatment. ACM Transactions on Multimedia Computing, Communications and Applications, 2020, 16, 1-23.	4.3	10
57	Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21‑gene recurrence score of 26‑30. Oncology Letters, 2020, 20, 1545-1556.	1.8	4
58	Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score–Adjusted, Population-Based Study. Cancer Research and Treatment, 2020, 52, 552-562.	3.0	16
59	Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study. Cancer Research and Treatment, 2020, 52, 671-679.	3.0	5
60	Long noncoding RNA HOXC-AS3 indicates a poor prognosis and regulates tumorigenesis by binding to YBX1 in breast cancer. American Journal of Translational Research (discontinued), 2020, 12, 6335-6350.	0.0	5
61	Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer. Journal of Breast Cancer, 2019, 22, 399.	1.9	10
62	21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes. Scientific Reports, 2019, 9, 13123.	3.3	13
63	Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nature Communications, 2019, 10, 4353.	12.8	193
64	<p>A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab</p>. Cancer Management and Research, 2019, Volume 11, 3371-3379.	1.9	13
65	Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample. Annals of Surgical Oncology, 2019, 26, 2779-2786.	1.5	13
66	Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1877-1886.	2.5	21
67	Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer. Journal of Cancer, 2019, 10, 1110-1116.	2.5	9
68	4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion. Breast Cancer Research and Treatment, 2019, 175, 567-578.	2.5	6
69	Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era. World Journal of Surgical Oncology, 2019, 17, 37.	1.9	18
70	Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1‑2N0M0, Estrogen Receptor‑Positive, Human Epidermal Growth Receptor 2‑Negative Invasive Breast Cancer: A Population‑Based Analysis. Oncologist, 2019, 24, e1014-e1023.	3.7	1
71	Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis. Clinical Breast Cancer, 2019, 19, e66-e73.	2.4	10
72	Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1521-1528.	4.9	16

#	Article	IF	Citations
73	CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer. American Journal of Translational Research (discontinued), 2019, 11, 1581-1592.	0.0	8
74	Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?. European Journal of Cancer, 2018, 89, 9-18.	2.8	20
75	The impact of surgical excision of the primary tumor in stage IV breast cancer on survival: a meta-analysis. Oncotarget, 2018, 9, 11816-11823.	1.8	17
76	Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen. Journal of Breast Cancer, 2018, 21, 277.	1.9	7
77	Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study. Journal of Cancer, 2018, 9, 3216-3224.	2.5	9
78	A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 222-230.	2.2	5
79	Quantitative measurement of total erbB2 (H2T), p110 t-erbB2, and erbB2:erbB3 (H23D) heterodimer expression and p110 t-erbB2 in malignant progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).. Journal of Clinical Oncology, 2018, 36, 12089-12089.	1.6	0
80	Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease?. Annals of Surgical Oncology, 2017, 24, 1874-1880.	1.5	6
81	Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study. Integrative Cancer Therapies, 2017, 16, 406-413.	2.0	14
82	A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer. Translational Oncology, 2017, 10, 988-997.	3.7	16
83	Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget, 2017, 8, 38706-38716.	1.8	31
84	Analysis of factors related to adjuvant chemotherapy decision in early breast cancer patients with intermediate recurrence score.. Journal of Clinical Oncology, 2017, 35, e12032-e12032.	1.6	0
85	Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. Oncotarget, 2016, 7, 57301-57309.	1.8	15
86	A Multi-disciplinary Medical Treatment Decision Support System with intelligent treatment recommendation. , 2016, , .		2
87	Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumor Biology, 2016, 37, 9825-9835.	1.8	52
88	Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. International Journal of Biochemistry and Cell Biology, 2016, 71, 12-23.	2.8	22
89	Diffusion-Weighted Imaging-guided MR Spectroscopy in Breast Lesions using Readout-Segmented Echo-Planar Imaging. European Radiology, 2016, 26, 1565-1574.	4.5	8
90	Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. Tumor Biology, 2016, 37, 4135-4142.	1.8	34

#	Article	IF	Citations
91	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0152500.	2.5	219
92	Biologic behavior and long-term outcomes of breast ductal carcinoma *in situ* with microinvasion. Oncotarget, 2016, 7, 64182-64190.	1.8	34
93	Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget, 2016, 7, 31079-31087.	1.8	34
94	Concurrent adjuvant radiochemotherapy versus standard chemotherapy followed by radiotherapy in operable breast cancer after breast conserving therapy: A meta-analysis. Journal of Cancer Research and Therapeutics, 2016, 12, 84.	0.9	10
95	Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. BMC Cancer, 2015, 15, 822.	2.6	34
96	Breast Cancer: Diffusion Kurtosis MR Imaging—Diagnostic Accuracy and Correlation with Clinical-Pathologic Factors. Radiology, 2015, 277, 46-55.	7.3	196
97	Effect of curcumin on lapatinib sensitivity and lapatinib resistance associated EMT and stem-like phenotype in HER2 positive breast cancer.. Journal of Clinical Oncology, 2015, 33, e11594-e11594.	1.6	1
98	The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e115103.	2.5	182
99	A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells. Oncology Reports, 2014, 32, 627-634.	2.6	6
100	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2014, 15, 580-591.	10.7	434
101	A novel long non-coding RNA-ARA: Adriamycin Resistance Associated. Biochemical Pharmacology, 2014, 87, 254-283.	4.4	100
102	Association of epithelial-mesenchymal transition with lapatinib resistance through multipe pathways activation in HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, e11579-e11579.	1.6	3
103	Effect of cancer-associated fibroblasts on trastuzumab resistance by activating multiple pathways in HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, e11587-e11587.	1.6	0